Two antibody-drug conjugates in solid tumours

Sacituzumab govitecan vs trastuzumab deruxtecan: trial pipelines compared

A side-by-side view of the sacituzumab govitecan and trastuzumab deruxtecan clinical trial pipelines, built from live ClinicalTrials.gov data and refreshed daily. ClinicalTrials.gov lists 16+ phase 2–4 trials for sacituzumab govitecan and 16+ for trastuzumab deruxtecan. Add up to three more drugs to widen the comparison.

sacituzumab govitecan (16) vs trastuzumab deruxtecan (16)29 active2017–2035

Hide completed

sacituzumab govitecantrastuzumab deruxtecan

Key

Actual date

Anticipated

Forecast to primary completion

RecruitingActive, not recruitingNot yet recruitingCompleted

'17

'19

'21

'23

'25

'27

'29

'31

'33

'35

sacituzumab govitecan

ASCENTP3

TROPiCS-02P3

InCITeP2

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBCP2

TROPiCS-04P3

Scalp Cooling in MBCP2

ASCENT-03P3

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)P2

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerP2

A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast CancerP2

ARIANP3

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBCP2

OASISP2

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerP3

ctDNA-guided Treatment Decision-makingP2

ADAPT-TN-IVP3

trastuzumab deruxtecan

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]P3

DG-03P2

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)P3

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerP3

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersP2

ARIADNEP2

ADAPTHER2-IVP2

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsP2

DEMETHERP2

T-DXd Versus THP for Medium-risk HER2-positive Early Breast CancerP2

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerP3

SURVIVE HERoesP3

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)P3

THUMBP2

DESTINY-Lung06P3

MEGA-TACT-BC3P3

Upcoming readouts

22 ahead · 2 drugs

Select a trial to load its full ClinicalTrials.gov record.

Head to head

Registered phase 2–4 trial activity for each drug, computed from live ClinicalTrials.gov data.

sacituzumab govitecan (Trodelvy)Antibody-drug conjugates

16+

Major trials tracked

Phase 3 trials

Actively recruiting

Jul 2028

Next phase 3 readout

trastuzumab deruxtecan (Enhertu)Antibody-drug conjugates

16+

Major trials tracked

Phase 3 trials

Actively recruiting

Jun 2028

Next phase 3 readout

Key trials across both drugs

Top 16 registered phase 2–4 trials across sacituzumab govitecan and trastuzumab deruxtecan, ordered by phase and status. Trial names open the full ComplyRx trial page; NCT ids link to ClinicalTrials.gov.

Drug	Trial	Title	Phase	Status	Primary completion
trastuzumab deruxtecan	NCT06731478	Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positi…	Phase 3	Recruiting	Jun 2028
trastuzumab deruxtecan	NCT07543536	MEGA-TACT-BC3: Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer	Phase 3	Recruiting	Apr 2029
trastuzumab deruxtecan	NCT06899126	DESTINY-Lung06: Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HE…	Phase 3	Recruiting	Apr 2030
sacituzumab govitecan	NCT06524544	A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standar…	Phase 3	Recruiting	Dec 2030
sacituzumab govitecan	NCT06431633	ARIAN: Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to t…	Phase 3	Recruiting	Nov 2031
trastuzumab deruxtecan	NCT06643585	SURVIVE HERoes: A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to…	Phase 3	Recruiting	Apr 2032
trastuzumab deruxtecan	NCT07060807	A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)	Phase 3	Recruiting	Jul 2033
trastuzumab deruxtecan	NCT03529110	DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable…	Phase 3	Active, not recruiting	May 2021
trastuzumab deruxtecan	NCT05113251	Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-TH…	Phase 3	Active, not recruiting	Mar 2025
trastuzumab deruxtecan	NCT04704934	Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junct…	Phase 3	Active, not recruiting	Aug 2026
sacituzumab govitecan	NCT05382299	ASCENT-03: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Prev…	Phase 3	Active, not recruiting	Jul 2028
sacituzumab govitecan	NCT07178730	ADAPT-TN-IV: NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinic…	Phase 3	Not yet recruiting	Mar 2033
sacituzumab govitecan	NCT02574455	ASCENT: Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negati…	Phase 3	Completed	Mar 2020
sacituzumab govitecan	NCT03901339	TROPiCS-02: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With …	Phase 3	Completed	Oct 2023
sacituzumab govitecan	NCT04527991	TROPiCS-04: Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Uroth…	Phase 3	Completed	Jul 2025
trastuzumab deruxtecan	NCT05900206	ARIADNE: Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer	Phase 2	Recruiting	Apr 2027

Track sacituzumab govitecan and trastuzumab deruxtecan with ComplyRx

Get an alert when a trial changes status, moves its completion date, or a new trial registers in scope. Checked nightly against ClinicalTrials.gov.

Track both drugs

FAQ

How do the sacituzumab govitecan and trastuzumab deruxtecan clinical pipelines compare?: ClinicalTrials.gov currently lists 16+ phase 2–4 trials for sacituzumab govitecan and 16+ for trastuzumab deruxtecan. The timeline above plots both side by side and refreshes daily.
Where does this data come from?: All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily. ComplyRx does not add efficacy or superiority claims; the comparison shows registered trial activity only.
Can I add more drugs to the comparison?: Yes. The tool above compares up to five drugs on one timeline, with PNG and PDF export. Add any competitor in the search box.

Upcoming readouts

Head to head

Key trials across both drugs

Track sacituzumab govitecan and trastuzumab deruxtecan with ComplyRx

Individual pipelines and other comparisons

FAQ

Be the first to access ComplyRx